Clinical integration of fast Raman spectroscopy for Mohs micrographic surgery of basal cell carcinoma
- PMID: 33996213
- PMCID: PMC8086475
- DOI: 10.1364/BOE.417896
Clinical integration of fast Raman spectroscopy for Mohs micrographic surgery of basal cell carcinoma
Abstract
We present the first clinical integration of a prototype device based on integrated auto-fluorescence imaging and Raman spectroscopy (Fast Raman device) for intra-operative assessment of surgical margins during Mohs micrographic surgery of basal cell carcinoma (BCC). Fresh skin specimens from 112 patients were used to optimise the tissue pre-processing and the Fast Raman algorithms to enable an analysis of complete Mohs layers within 30 minutes. The optimisation allowed >95% of the resection surface area to be investigated (including the deep and epidermal margins). The Fast Raman device was then used to analyse skin layers excised from the most relevant anatomical sites (nose, temple, eyelid, cheek, forehead, eyebrow and lip) and to detect the three main types of BCC (nodular, superficial and infiltrative). These results suggest that the Fast Raman technique is a promising tool to provide an objective diagnosis "tumour clear yes/no" during Mohs surgery of BCC. This clinical integration study is a key step towards a larger scale diagnosis test accuracy study to reliably determine the sensitivity and specificity in a clinical setting.
Published by The Optical Society under the terms of the Creative Commons Attribution 4.0 License. Further distribution of this work must maintain attribution to the author(s) and the published article’s title, journal citation, and DOI.
Conflict of interest statement
I Notingher, H Williams, S Varma, A. Koloydenko hold a patent related to the Fast Raman technology. The Fast Raman device was built by RiverD International.
Figures
Similar articles
-
Diagnostic accuracy of autofluorescence-Raman spectroscopy for surgical margin assessment during Mohs micrographic surgery of basal cell carcinoma.Br J Dermatol. 2024 May 13:ljae196. doi: 10.1093/bjd/ljae196. Online ahead of print. Br J Dermatol. 2024. PMID: 38736216
-
Surgical margins required for basal cell carcinomas treated with Mohs micrographic surgery according to tumor features.J Am Acad Dermatol. 2020 Aug;83(2):493-500. doi: 10.1016/j.jaad.2020.04.008. Epub 2020 Apr 11. J Am Acad Dermatol. 2020. PMID: 32289390
-
Optimization of multimodal spectral imaging for assessment of resection margins during Mohs micrographic surgery for basal cell carcinoma.Biomed Opt Express. 2014 Dec 10;6(1):98-111. doi: 10.1364/BOE.6.000098. eCollection 2015 Jan 1. Biomed Opt Express. 2014. PMID: 25657878 Free PMC article.
-
Who should have Mohs micrographic surgery?Curr Opin Otolaryngol Head Neck Surg. 2010 Aug;18(4):283-9. doi: 10.1097/MOO.0b013e32833b6f19. Curr Opin Otolaryngol Head Neck Surg. 2010. PMID: 20613530 Review.
-
Mohs Micrographic Surgery for skin cancer.Australas J Dermatol. 1991;32(3):159-64. doi: 10.1111/j.1440-0960.1991.tb01783.x. Australas J Dermatol. 1991. PMID: 1823112 Review.
Cited by
-
Co-localized line-field confocal optical coherence tomography and confocal Raman microspectroscopy for three-dimensional high-resolution morphological and molecular characterization of skin tissues ex vivo.Biomed Opt Express. 2022 Mar 25;13(4):2467-2487. doi: 10.1364/BOE.450993. eCollection 2022 Apr 1. Biomed Opt Express. 2022. PMID: 35519243 Free PMC article.
-
The complementary value of intraoperative fluorescence imaging and Raman spectroscopy for cancer surgery: combining the incompatibles.Eur J Nucl Med Mol Imaging. 2022 Jun;49(7):2364-2376. doi: 10.1007/s00259-022-05705-z. Epub 2022 Feb 1. Eur J Nucl Med Mol Imaging. 2022. PMID: 35102436 Free PMC article. Review.
-
Emerging Minimally Invasive Technologies for the Detection of Skin Cancer.J Pers Med. 2021 Sep 24;11(10):951. doi: 10.3390/jpm11100951. J Pers Med. 2021. PMID: 34683091 Free PMC article. Review.
References
-
- Global Burden of Disease Cancer , “Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the global burden of disease study,” JAMA Oncology 5(12), 1749–1768 (2019).10.1001/jamaoncol.2019.2996 - DOI - PMC - PubMed
-
- Mosterd K., Krekels G. A., Nieman F. H., Ostertag J. U., Essers B. A., Dirksen C. D., Steijlen P. M., Vermeulen A., Neumann H., Kelleners-Smeets N. W., “Surgical excision versus Mohs’ micrographic surgery for primary and recurrent basal-cell carcinoma of the face: a prospective randomised controlled trial with 5-years’ follow-up,” Lancet Oncol. 9(12), 1149–1156 (2008).10.1016/S1470-2045(08)70260-2 - DOI - PubMed
-
- Flohil S. C., van Dorst A. M. J. M., Nijsten T., Martino Neumann H. A., Munte K., “Mohs micrographic surgery for basal cell carcinomas: appropriateness of ‘Rotterdam’ criteria and predictive factors for three or more stages,” Journal of the European Academy of Dermatology and Venereology 27(7), 907–911 (2013).10.1111/j.1468-3083.2011.04407.x - DOI - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources